Pilot Study of Vitamin D Supplementation in Adults with Cystic Fibrosis Pulmonary Exacerbation: A Randomized, Controlled Trial

Overview

Journal Dermatoendocrinol

Specialty Endocrinology

Date 2012 Aug 29

PMID 22928076

Citations 36

Authors

Ruth E Grossmann

Susu M Zughaier

Meena Kumari

Shabnam Seydafkan

Robert H Lyles

Shuling Liu

Viranuj Sueblinvong

Michael S Schechter

Arlene A Stecenko

Thomas R Ziegler

Vin Tangpricha

Affiliations

Soon will be listed here.

Abstract

Unlabelled:

Background: Vitamin D insufficiency is common in cystic fibrosis (CF) and vitamin D repletion may have an important role in improving clinical outcomes in CF. This randomized, placebo-controlled, pilot study examined the feasibility and impact of a single, large dose of cholecalciferol on vitamin D status and clinical outcomes in subjects with CF.

Methods: Thirty adults with were randomized in a double-blinded, pilot study to receive 250,000 IU cholecalciferol or placebo within 48 h of hospital admission for a pulmonary exacerbation. Concentrations of 25-hydroxyvitamin D (25(OH)D), clinical outcomes and potential adverse events were assessed up to one year after randomization. Mixed effects linear regression models were used to evaluate the difference in mean serum concentrations and log-rank analyses were used to evaluate survival.

Results: Data from all subjects was analyzed. Serum 25(OH)D concentrations increased from a mean of 30.6 ± 3.2 ng/mL to 58.1 ± 3.5 ng/mL (p < 0.001) at one week and 36.7 ± 2.6 ng/mL by 12 weeks (p = 0.06) in the vitamin D group; in contrast, serum 25(OH)D concentrations remained unchanged in the placebo group. Unadjusted, one-year survival and hospital-free days were increased in the vitamin D group (p = 0.029, p = 0.036; respectively). There was also a trend toward increased IV antibiotic therapy-free days in the vitamin D group (p = 0.073). There were no signs of hypervitaminosis D or adverse events. Serum PTH and calcium concentrations were similar across both groups.

Conclusions: In this pilot study, a single, oral bolus of cholecalciferol increased serum 25(OH)D concentrations and was associated with a trend toward improved clinical outcomes in CF subjects hospitalized for a pulmonary exacerbation. Further investigation is needed into the clinical impact of improved vitamin D status in patients with CF.

Citing Articles

Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Hu C, Binongo J, Hunt W Contemp Clin Trials Commun. 2024; 38:101278.

PMID: 38435430 PMC: 10904905. DOI: 10.1016/j.conctc.2024.101278.

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D Trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Binongo J, Hunt W, Gewirtz A medRxiv. 2024; .

PMID: 38343811 PMC: 10854319. DOI: 10.1101/2024.01.04.24300860.

Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.

Farahbakhsh N, Fatahi S, Shirvani A, Motaharifard M, Mohkam M, Tabatabaii S J Health Popul Nutr. 2024; 43(1):11.

PMID: 38233891 PMC: 10795301. DOI: 10.1186/s41043-024-00499-2.

The effects of vitamin D on all-cause mortality in different diseases: an evidence-map and umbrella review of 116 randomized controlled trials.

Cao M, He C, Gong M, Wu S, He J Front Nutr. 2023; 10:1132528.

PMID: 37426183 PMC: 10325578. DOI: 10.3389/fnut.2023.1132528.

Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis.

Wu M, Bhimavarapu A, Alvarez J, Hunt W, Tangpricha V Bone. 2023; 174:116835.

PMID: 37390941 PMC: 10428002. DOI: 10.1016/j.bone.2023.116835.

References

Boas S, Hageman J, Ho L, Liveris M . Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009; 8(4):270-2. DOI: 10.1016/j.jcf.2009.04.004. View

Green D, Leonard A, Paranjape S, Rosenstein B, Zeitlin P, Mogayzel Jr P . Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010; 9(2):143-9. DOI: 10.1016/j.jcf.2010.01.002. View

Wolfenden L, Judd S, Shah R, Sanyal R, Ziegler T, Tangpricha V . Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf). 2008; 69(3):374-81. PMC: 2851223. DOI: 10.1111/j.1365-2265.2008.03216.x. View

Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V . Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr. 2012; 95(2):522-8. PMC: 3260077. DOI: 10.3945/ajcn.111.025502. View

Leventis P, Kiely P . The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2008; 38(2):149-53. DOI: 10.1080/03009740802419081. View

Aris R, Merkel P, Bachrach L, Borowitz D, Boyle M, Elkin S . Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2004; 90(3):1888-96. DOI: 10.1210/jc.2004-1629. View

Jeffery L, Burke F, Mura M, Zheng Y, Qureshi O, Hewison M . 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009; 183(9):5458-67. PMC: 2810518. DOI: 10.4049/jimmunol.0803217. View

Boyle M, Noschese M, Watts S, Davis M, Stenner S, Lechtzin N . Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005; 172(2):212-7. PMC: 2718468. DOI: 10.1164/rccm.200403-387OC. View

West N, Lechtzin N, Merlo C, Turowski J, Davis M, Ramsay M . Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. Chest. 2011; 140(2):469-474. DOI: 10.1378/chest.10-2114. View

10.

Braun A, Chang D, Mahadevappa K, Gibbons F, Liu Y, Giovannucci E . Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med. 2011; 39(4):671-7. PMC: 3448785. DOI: 10.1097/CCM.0b013e318206ccdf. View

11.

Belderbos M, Houben M, Wilbrink B, Lentjes E, Bloemen E, Kimpen J . Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011; 127(6):e1513-20. DOI: 10.1542/peds.2010-3054. View

12.

Finklea J, Grossmann R, Tangpricha V . Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studies. Adv Nutr. 2012; 2(3):244-53. PMC: 3090167. DOI: 10.3945/an.111.000398. View

13.

Liu P, Stenger S, Li H, Wenzel L, Tan B, Krutzik S . Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768):1770-3. DOI: 10.1126/science.1123933. View

14.

Green D, Carson K, Leonard A, Davis J, Rosenstein B, Zeitlin P . Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008; 153(4):554-9. DOI: 10.1016/j.jpeds.2008.04.058. View

15.

Forli L, Bjortuft O, BOE J . Vitamin D status in relation to nutritional depletion and muscle function in patients with advanced pulmonary disease. Exp Lung Res. 2009; 35(6):524-38. DOI: 10.1080/01902140902763193. View

16.

De Boer K, Vandemheen K, Tullis E, Doucette S, Fergusson D, Freitag A . Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011; 66(8):680-5. DOI: 10.1136/thx.2011.161117. View

17.

Melamed M, Michos E, Post W, Astor B . 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168(15):1629-37. PMC: 2677029. DOI: 10.1001/archinte.168.15.1629. View

18.

Kerem E, Reisman J, Corey M, Canny G, Levison H . Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326(18):1187-91. DOI: 10.1056/NEJM199204303261804. View

19.

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

20.

Boucher B . The 2010 recommendations of the American Institute of Medicine for daily intakes of vitamin D. Public Health Nutr. 2011; 14(4):740. DOI: 10.1017/S136898001100022X. View